ArticleHepatology communications2019
Correlation of Immune Markers With Outcomes in Biliary Atresia Following Intravenous Immunoglobulin Therapy.
Article in Hepatology communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- CD38+ NK cells: novel players in immunoregulation.Frontiers in immunology · 2026Review
- Immunohistochemical Expression of HLA Classes I and II in Neonatal Cholestatic Liver Disease.Iranian journal of pathology · 2026Article
- Increased serum GM-CSF at diagnosis of biliary atresia is associated with improved biliary drainage.Pediatric research · 2025Article
- Dramatic Extrahepatic Cholestasis Improvement after Steroid Therapy.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Article
- Advances in research on the role of neutrophils in organ transplant rejection.Frontiers in immunology · 2025Review
- Correlation of the Expression Profile of Peripheral Leukocyte and Liver Tissue Immune Markers With Serum Liver Injury Indices in Children With Biliary Atresia.Mediators of inflammation · 2025Article
- Immunology of Biliary Atresia.Seminars in pediatric surgery · 2024Review
- Biliary atresia.Nature reviews. Disease primers · 2024Review
- Single cell RNA-sequencing analysis reveals thatJHEP reports : innovation in hepatology · 2023Article
- Potential therapeutic target of EGF on bile duct ligation model and biliary atresia children.Pediatric research · 2023Article
- Pre- and Immediate Post-Kasai Portoenterostomy Shear Wave Elastography for Predicting Hepatic Fibrosis and Native Liver Outcomes in Patients With Biliary Atresia.Korean journal of radiology · 2023Article
- Editorial: Elimination of biliary atresia.Frontiers in pediatrics · 2023Article
- Biliary Atresia in Children: Update on Disease Mechanism, Therapies, and Patient Outcomes.Clinics in liver disease · 2022Review
- Circulating maternal chimeric cells have an impact on the outcome of biliary atresia.Frontiers in pediatrics · 2022Article
- Regulatory T Cell (Treg) Cytotoxic T Lymphocyte-associated Antigen-4 Deficits in Biliary Atresia (BA) and Disease Rescue With Treg Augmentation in Murine BA.Gastro hep advances · 2022Article
- Review
- Association of Gut Microbiota and Metabolites With Disease Progression in Children With Biliary Atresia.Frontiers in immunology · 2021Article
- Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders.Hepatology international · 2020Review
- Unexpected Improvement of Liver Function by Intravenous Immunoglobulin in a Steroid-Experienced Severe Alcoholic Hepatitis.ACG case reports journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 11 institutions in 2 countries.
Funding
Abstract
Biliary atresia is a progressive fibroinflammatory cholangiopathy of infancy that is associated with activation of innate and adaptive immune responses targeting bile ducts. A recently completed multicenter phase I/IIA trial of intravenous immunoglobulin in biliary atresia did not improve serum total bilirubin levels at 90 days after hepatoportoenterostomy or survival with the native liver at 1 year. A mechanistic aim of this trial was to determine if the peripheral blood immunophenotype was associated with clinical outcomes. Flow cytometry of peripheral blood cell markers (natural killer [NK], macrophage subsets, T- and B-cell subsets, regulatory T cells), neutrophils, and activation markers (clusters of differentiation [CD]38, CD69, CD86, human leukocyte antigen-DR isotype [HLA-DR]) was performed on 29 patients with biliary atresia at baseline and at 60, 90, 180, and 360 days after hepatoportoenterostomy. Plasma cytokines and neutrophil products were also measured. Spearman correlations of change of an immune marker from baseline to day 90 with change in serum bilirubin revealed that an increase in total bilirubin correlated with 1) increased percentage of HLA-DR
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.